Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temuterkib - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Temuterkib - Eli Lilly and Company

Alternative Names: LY-3214996; LY3518429; Temuterkib mesylate - Eli Lilly and Company

Latest Information Update: 08 Mar 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Dana-Farber Cancer Institute; Eli Lilly and Company; Netherlands Cancer Institute; The Lustgarten Foundation
  • Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Morpholines; Pyrazoles; Pyrimidines; Pyrrolidinones; Small molecules; Thiophenes
  • Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer; Pancreatic cancer; Solid tumours
  • Phase I Colorectal cancer; Non-small cell lung cancer
  • No development reported Acute myeloid leukaemia; Glioblastoma

Most Recent Events

  • 05 Feb 2024 Eli Lilly and Company and Dana Farber Cancer Institute completes a phase II trial in Pancreatic cancer (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04386057)
  • 20 Oct 2023 Pharmacokinetics, efficacy and adverse events data from the phase I/Ib SHERPA trial presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 28 Aug 2023 No recent reports of development identified for phase-0 development in Glioblastoma(Combination therapy, Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top